11 results match your criteria: "Institute of Oncotherapy[Affiliation]"
Cancers (Basel)
April 2024
Institute of Oncotherapy, Clinical Center and Medical School, University of Pécs, 7624 Pécs, Hungary.
Aim: The complex medical care of synchronous metastatic colorectal (smCRC) patients requires prudent multidisciplinary planning and treatments due to various challenges caused by the primary tumor and its metastases. The role of primary tumor resection (PTR) is currently uncertain; strong arguments exist for and against it. We aimed to define its effect and find its best place in our therapeutic methodology.
View Article and Find Full Text PDFCancers (Basel)
October 2023
Institute of Oncotherapy, Medical School and Clinical Center, University of Pécs, 7624 Pécs, Hungary.
Aim: The oncologic treatment of elderly patients is going on with a lack of evidence due to their underrepresentation in clinical trials. Many data suggest that certain groups of elderly patients, like their younger counterparts, may benefit from the systemic treatment of their metastatic colorectal tumors (mCRC).
Method: We performed retrospective data analysis to investigate the clinical course of care and clinical outcomes of 515 patients who received first-line mFOLFIRI-based chemotherapy for mCRC between 1 January 2013 and 31 December 2018 at the Institute of Oncotherapy of the University of Pécs, focusing on a comparison of patients over and under 70 years of age, defined as the cut-off value.
Pathol Oncol Res
January 2023
Center of Oncoradiology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary.
[This corrects the article DOI: 10.3389/pore.2022.
View Article and Find Full Text PDFCurr Oncol
January 2023
Clinical Centre and Medical School, Institute of Oncotherapy, University of Pécs, H-7624 Pécs, Hungary.
Aim: The key purposes of the treatment of metastatic malignancies are to extend survival and maintain the quality of life. Recently it has been emphasized in the scientific literature that the maintenance of maximal dose intensity is not always beneficial. Method: We examined the effectiveness of first-line mFOLFIRI-based treatments used in mCRC indication in 515 patients, treated between 1 January 2013 and 31 December 2018 at the Department of Oncotherapy of the University of Pécs, on a basis of real-world retrospective data analysis.
View Article and Find Full Text PDFPathol Oncol Res
July 2022
Center of Oncoradiology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary.
This text is based on the recommendations accepted by the 4th Hungarian Consensus Conference on Breast Cancer, modified based on the international consultation and conference within the frames of the Central-Eastern European Academy of Oncology. The professional guideline primarily reflects the resolutions and recommendations of the current ESMO, NCCN and ABC5, as well as that of the St. Gallen Consensus Conference statements.
View Article and Find Full Text PDFPathol Oncol Res
January 2019
National Institute of Oncology, Chemotherapy C and Clinical Pharmacology, Ráth György str. 7-9, Budapest, Hungary.
Everolimus is indicated for adults with metastatic renal cell carcinoma (mRCC) after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (TKI). Currently, the therapeutic applicability of EVE has been changing. Multicenter evaluation of efficacy and safety of everolimus in daily routine and definition of patient characteristics with favorable outcome.
View Article and Find Full Text PDFBMC Cancer
December 2015
Institute of Pathology, University of Pécs, Pécs, Hungary.
Background: Treatment possibilities of metastatic renal cell carcinoma (mRCC) have recently changed dramatically prolonging the overall survival of the patients. This kind of development brings new challenges for the care of mRCC.
Case Presentation: A 22 year-old female patient with translocation type mRCC, who previously had been treated for nearly 5 years, became pregnant during the treatment break period.
Med Dosim
November 2011
Institute of Oncotherapy, University of Pécs, Pécs, Hungary.
A pelvic phantom was developed for use in testing image-guided radiation therapy (IGRT) and adaptive applications in radiation therapy (ART) with simulating the anterior-posterior internal organ motions during prostate radiotherapy. Measurements could be done with an ionization chamber (IC) in the simulated prostate. The rectum was simulated by air-equivalent material (AEM).
View Article and Find Full Text PDFMed Dosim
June 2011
University of Pécs, Institute of Oncotherapy, Pécs, Hungary.
When treating pancreatic cancer using standard (ST) 3D conformal radiotherapy (3D-CRT) beam arrangements, the kidneys often receive a higher dose than their probable tolerance limit. Our aim was to elaborate a new planning method that--similarly to IMRT--effectively spares the kidneys without compromising the target coverage. Conformal kidneys sparing (CONKISS) 5-field, noncoplanar plans were compared with ST plans for 23 consecutive patients retrospectively.
View Article and Find Full Text PDFJ Biol Chem
January 2010
Institute of Oncotherapy, University of Pécs, 12 Szigeti Street, Pécs H-7624, Hungary.
We identified a sequence homologous to the Bcl-2 homology 3 (BH3) domain of Bcl-2 proteins in SOUL. Tissues expressed the protein to different extents. It was predominantly located in the cytoplasm, although a fraction of SOUL was associated with the mitochondria that increased upon oxidative stress.
View Article and Find Full Text PDFFEBS Lett
November 2006
Institute of Oncotherapy, University of Pécs, Pécs, Hungary.
We found that heme-binding protein 2/SOUL sensitised NIH3T3 cells to cell death induced by A23187 and etoposide, but it did not affect reactive oxygen species formation. In the presence of sub-threshold calcium, recombinant SOUL provoked mitochondrial permeability transition (mPT) in vitro that was inhibited by cyclosporine A (CsA). This effect was verified in vivo by monitoring the dissipation of mitochondrial membrane potential.
View Article and Find Full Text PDF